Latest Biologicals News

Noxopharm has unveiled new data showing its Sofra technology dramatically boosts TLR8 activation, a key immune pathway, potentially reshaping cancer immunotherapy.

New Zealand King Salmon (NZK) reversed prior losses with a $13.8 million net profit in 1HY26, upgrading its full-year earnings outlook and advancing key growth infrastructure.

TrivarX has contracted Beyond Drug Development to drive its Stabl-Im MRI imaging platform into Phase 1 trials, aiming to start safety testing in healthy volunteers by late 2026.

Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.

Island Pharmaceuticals has appointed Mark Herzog as Senior Global Health Security Advisor and secured roles in key Medical Countermeasures Coalition groups, boosting its US biodefence engagement ahead of pivotal Galidesivir Animal Rule studies.

Algorae Pharmaceuticals has scaled its AI-driven drug synergy platform from one to 18 anchor drugs, generating over 9 million predictions and identifying thousands of promising combinations for cancer and other diseases.

Amplia Therapeutics and ANZGOG have initiated a clinical trial to test narmafotinib combined with chemotherapy in ovarian cancer patients unresponsive to platinum-based treatment, aiming to improve surgical outcomes and explore biomarker insights.

Murray Cod Australia (ASX:MCA) has launched the retail tranche of its fully underwritten $18.6 million entitlement offer at a 43% discount, aiming to convert its record 3,700-tonne biomass into cash and expand processing capacity.

BPH Global inks binding deal with Temasek Innovation Holdings to validate its seaweed-based male vitality product through targeted biological assays, advancing regulatory and commercial ambitions.

Murray Cod Australia (ASX:MCA) is raising $18.6 million through a fully underwritten entitlement offer at a steep 43% discount to last price, aiming to convert its record 3,700-tonne biomass into sales and expand processing capacity.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.